Roscoe Brunton
SubscribersAbout
Because of its diverse role, low levels of testosterone can cause a wide range of symptoms including erectile dysfunction, low libido, and decreased muscle mass and strength. Are declining testosterone levels not just a normal part of ageing? Because it can be different from person to person, it's important to learn the signs and symptoms you have when your blood glucose levels are low. Part of living with diabetes is fluctuations in your blood glucose levels. If you have higher-than-normal hormone levels, there are many treatment options depending on the cause. Certain hormone levels vary drastically throughout the day, so providers may order other tests to measure your levels, such as a glucose tolerance test or insulin tolerance test.
The decrease was more noticeable in men who were overweight or had high blood sugar before starting treatment. Fasting blood sugar is the level of glucose in the blood after not eating for at least eight hours. Because the therapy can have risks, it must be monitored carefully with regular check-ups and blood tests. Testosterone therapy is used to treat men with low levels of this important hormone.
Testosterone therapy may also affect the prostate, a small gland in men that helps produce semen. Still, doctors are careful when prescribing testosterone to men with a history of heart attack, stroke, or other serious heart conditions. Still, doctors must consider the possible risks and the need for careful monitoring. More research is needed to understand which patients are the best candidates for therapy. Some doctors worry about heart problems, prostate issues, or thickening of the blood. Although the T4DM study showed promising results, there are still questions. The other group received a placebo gel that looked the same but had no testosterone.
The study findings were presented this Monday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco. It was a retrospective study, meaning the researchers analyzed existing medical records over time, rather than conducting a randomized clinical trial. Increases in haematocrit might be treatment limiting.
Because of this, men are usually tested for prostate cancer using a PSA (prostate-specific antigen) blood test before starting treatment. Understanding these risks is important before starting or continuing therapy. These risks need to be weighed carefully when considering treatment. Chronic inflammation is believed to play a role in the development of insulin resistance and type 2 diabetes. Visceral fat (fat stored deep inside the belly) is known to cause inflammation and insulin resistance. Testosterone therapy may help prevent type 2 diabetes in several ways.
However, some men with low testosterone may not show clear signs at all. These can appear slowly and be mistaken for other health problems or aging. Many men may not know they have this problem until they notice certain symptoms. These signs may point to a condition called testosterone deficiency or hypogonadism. Levels below 300 ng/dL are often considered low, especially if the person also has symptoms like low energy, poor sleep, reduced sex drive, or weight gain.
Clinicians can use this information to assess the possible hazards and advantages of testosterone therapy for their patients. According to various cross-sectional studies, there was no connection between raised serum lipid levels or even elevated LDL in patients with high endogenous testosterone profiles 2,3,4. Increased peripheral glucose uptake and better insulin sensitivity may result from testosterone’s ability to promote the translocation of glucose transporter type 4 (GLUT4) to myocyte membranes. Further interventional studies are needed to fully understand the association between circulating sex hormones and glucose metabolism. Regarding glucometabolic outcomes, our findings show that TRT can greatly enhance glucose control by improving declines in HOMA-IR, FSG, FSI, and glycated hemoglobin (HBA1C), as previously established in other studies 5,8,12,13,20,21,22,23,24. This systematic review aimed to develop clear, evidence-based recommendations for treating hypogonadism in males with type 2 diabetes mellitus by administering testosterone replacement therapy. A total of 1 study utilized oral testosterone, 3 16,18,22 used testosterone gel by the transdermal method, and 11 used testosterone by a deep intramuscular injection 5,8,12,13,14,15,17,19,20,21,23,24.
The decrease was more noticeable in men who were overweight or had high blood sugar before starting treatment. Fasting blood sugar is the level of glucose in the blood after not eating for at least eight hours. Because the therapy can have risks, it must be monitored carefully with regular check-ups and blood tests. Testosterone therapy is used to treat men with low levels of this important hormone.
Testosterone therapy may also affect the prostate, a small gland in men that helps produce semen. Still, doctors are careful when prescribing testosterone to men with a history of heart attack, stroke, or other serious heart conditions. Still, doctors must consider the possible risks and the need for careful monitoring. More research is needed to understand which patients are the best candidates for therapy. Some doctors worry about heart problems, prostate issues, or thickening of the blood. Although the T4DM study showed promising results, there are still questions. The other group received a placebo gel that looked the same but had no testosterone.
The study findings were presented this Monday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco. It was a retrospective study, meaning the researchers analyzed existing medical records over time, rather than conducting a randomized clinical trial. Increases in haematocrit might be treatment limiting.
Because of this, men are usually tested for prostate cancer using a PSA (prostate-specific antigen) blood test before starting treatment. Understanding these risks is important before starting or continuing therapy. These risks need to be weighed carefully when considering treatment. Chronic inflammation is believed to play a role in the development of insulin resistance and type 2 diabetes. Visceral fat (fat stored deep inside the belly) is known to cause inflammation and insulin resistance. Testosterone therapy may help prevent type 2 diabetes in several ways.
However, some men with low testosterone may not show clear signs at all. These can appear slowly and be mistaken for other health problems or aging. Many men may not know they have this problem until they notice certain symptoms. These signs may point to a condition called testosterone deficiency or hypogonadism. Levels below 300 ng/dL are often considered low, especially if the person also has symptoms like low energy, poor sleep, reduced sex drive, or weight gain.
Clinicians can use this information to assess the possible hazards and advantages of testosterone therapy for their patients. According to various cross-sectional studies, there was no connection between raised serum lipid levels or even elevated LDL in patients with high endogenous testosterone profiles 2,3,4. Increased peripheral glucose uptake and better insulin sensitivity may result from testosterone’s ability to promote the translocation of glucose transporter type 4 (GLUT4) to myocyte membranes. Further interventional studies are needed to fully understand the association between circulating sex hormones and glucose metabolism. Regarding glucometabolic outcomes, our findings show that TRT can greatly enhance glucose control by improving declines in HOMA-IR, FSG, FSI, and glycated hemoglobin (HBA1C), as previously established in other studies 5,8,12,13,20,21,22,23,24. This systematic review aimed to develop clear, evidence-based recommendations for treating hypogonadism in males with type 2 diabetes mellitus by administering testosterone replacement therapy. A total of 1 study utilized oral testosterone, 3 16,18,22 used testosterone gel by the transdermal method, and 11 used testosterone by a deep intramuscular injection 5,8,12,13,14,15,17,19,20,21,23,24.
